Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.

OBJECTIVES To determine how we define good practice in sensitivity analysis in general and probabilistic sensitivity analysis (PSA) in particular, and to what extent it has been adhered to in the independent economic evaluations undertaken for the National Institute for Health and Clinical Excellence (NICE) over recent years; to establish what policy impact sensitivity analysis has in the context of NICE, and policy-makers' views on sensitivity analysis and uncertainty, and what use is made of sensitivity analysis in policy decision-making. DATA SOURCES Three major electronic databases, MEDLINE, EMBASE and the NHS Economic Evaluation Database, were searched from inception to February 2008. REVIEW METHODS The meaning of 'good practice' in the broad area of sensitivity analysis was explored through a review of the literature. An audit was undertaken of the 15 most recent NICE multiple technology appraisal judgements and their related reports to assess how sensitivity analysis has been undertaken by independent academic teams for NICE. A review of the policy and guidance documents issued by NICE aimed to assess the policy impact of the sensitivity analysis and the PSA in particular. Qualitative interview data from NICE Technology Appraisal Committee members, collected as part of an earlier study, were also analysed to assess the value attached to the sensitivity analysis components of the economic analyses conducted for NICE. RESULTS All forms of sensitivity analysis, notably both deterministic and probabilistic approaches, have their supporters and their detractors. Practice in relation to univariate sensitivity analysis is highly variable, with considerable lack of clarity in relation to the methods used and the basis of the ranges employed. In relation to PSA, there is a high level of variability in the form of distribution used for similar parameters, and the justification for such choices is rarely given. Virtually all analyses failed to consider correlations within the PSA, and this is an area of concern. Uncertainty is considered explicitly in the process of arriving at a decision by the NICE Technology Appraisal Committee, and a correlation between high levels of uncertainty and negative decisions was indicated. The findings suggest considerable value in deterministic sensitivity analysis. Such analyses serve to highlight which model parameters are critical to driving a decision. Strong support was expressed for PSA, principally because it provides an indication of the parameter uncertainty around the incremental cost-effectiveness ratio. CONCLUSIONS The review and the policy impact assessment focused exclusively on documentary evidence, excluding other sources that might have revealed further insights on this issue. In seeking to address parameter uncertainty, both deterministic and probabilistic sensitivity analyses should be used. It is evident that some cost-effectiveness work, especially around the sensitivity analysis components, represents a challenge in making it accessible to those making decisions. This speaks to the training agenda for those sitting on such decision-making bodies, and to the importance of clear presentation of analyses by the academic community.

[1]  C. Normand,et al.  Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. , 2000, Health technology assessment.

[2]  J Lipscomb,et al.  Assessing Uncertainty in Cost-Effectiveness Analyses , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  Simon Finfer,et al.  SAFE (The Saline versus Albumin Fluid Evaluation) 試験 , 2006 .

[4]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[5]  M. Smith,et al.  Systematic review of endoscopic ultrasound in gastro-oesophageal cancer. , 1998, Health Technology Assessment.

[6]  M. Pitt,et al.  Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. , 2008, Health technology assessment.

[7]  J Chilcott,et al.  A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. , 2003, Health technology assessment.

[8]  D. Jayne Stapled haemorrhoidopexy for the treatment of haemorrhoids. , 2009, Gastroenterologie clinique et biologique.

[9]  S. Bryan,et al.  Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment. , 2002, Health technology assessment.

[10]  K Tolley,et al.  The effectiveness of domiciliary health visiting: a systematic review of international studies and a selective review of the British literature. , 2000, Health technology assessment.

[11]  P Barton,et al.  Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. , 2005, Health technology assessment.

[12]  D G Altman,et al.  Indirect comparisons of competing interventions. , 2005, Health technology assessment.

[13]  N. Waugh,et al.  Screening for gestational diabetes: a systematic review and economic evaluation. , 2002, Health technology assessment.

[14]  K. Jolly,et al.  Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. , 2000, Health technology assessment.

[15]  C. Czoski-Murray,et al.  Extended scope of nursing practice: a multicentre randomised controlled trial of appropriately trained nurses and pre-registration house officers in pre-operative assessment in elective general surgery. , 2001, Health technology assessment.

[16]  P Wainwright,et al.  Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations. , 2004, Health technology assessment.

[17]  J Gabbay,et al.  'Early warning systems' for identifying new healthcare technologies. , 1999, Health technology assessment.

[18]  David R. Jones,et al.  A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. , 2003, Health technology assessment.

[19]  Stirling Bryan,et al.  Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. , 2007, Health economics.

[20]  J. Fox-Rushby,et al.  Allowing for uncertainty in economic evaluations: qualitative sensitivity analysis. , 2001, Health policy and planning.

[21]  P. Royle,et al.  Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. , 2002, Health technology assessment.

[22]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[23]  J. Dretzke,et al.  Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus. , 2004, Health technology assessment.

[24]  M. Sculpher,et al.  Making decisions under uncertainty--the role of probabilistic decision modelling. , 2006, Family practice.

[25]  P Sutcliffe,et al.  Health technology assessment. , 1986, Israel journal of medical sciences.

[26]  M K Campbell,et al.  Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. , 2004, Health technology assessment.

[27]  E Berry,et al.  The cost-effectiveness of magnetic resonance angiography for carotid artery stenosis and peripheral vascular disease: a systematic review. , 2002, Health technology assessment.

[28]  D. Symmons,et al.  A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. , 2006, Health technology assessment.

[29]  M Knapp,et al.  Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. , 2005, Health technology assessment.

[30]  A Haycox,et al.  Coronary artery stents: a rapid systematic review and economic evaluation. , 2004, Health technology assessment.

[31]  N. Waugh,et al.  Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. , 2000, Health technology assessment.

[32]  C. Bull,et al.  Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis. , 2005, Health technology assessment.

[33]  M. McDonagh,et al.  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. , 2000, Health technology assessment.

[34]  S. Paisley,et al.  Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation. , 2006, Health technology assessment.

[35]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[36]  A. Silman,et al.  Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis. , 2004, Health technology assessment.

[37]  A. Culyer,et al.  Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews. , 1998, Health technology assessment.

[38]  T. Sheldon,et al.  What role for statins? A review and economic model. , 1999, Health technology assessment.

[39]  P. Barry,et al.  Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. , 2001, Health technology assessment.

[40]  C. Beverley,et al.  Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. , 2005, Health technology assessment.

[41]  K E Willard,et al.  Probabilistic Analysis of Decision Trees Using Monte Carlo Simulation , 1986, Medical decision making : an international journal of the Society for Medical Decision Making.

[42]  Bas Groot Koerkamp,et al.  Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[43]  A. Glenny,et al.  Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials , 1998, Health technology assessment.

[44]  R. Milne,et al.  Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. , 2000, Health technology assessment.

[45]  J Gabbay,et al.  Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach. , 2004, Health technology assessment.

[46]  F. Song,et al.  Evaluating non-randomised intervention studies. , 2003, Health technology assessment.

[47]  S. Paisley,et al.  Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. , 2003, Health technology assessment.

[48]  P. Royle,et al.  Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. , 2003, Health technology assessment.

[49]  M. Mugford,et al.  The Social Support and Family Health Study: a randomised controlled trial and economic evaluation of two alternative forms of postnatal support for mothers living in disadvantaged inner-city areas. , 2004, Health technology assessment.

[50]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[51]  C Fraser,et al.  Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation. , 2005, Health technology assessment.

[52]  M Sculpher,et al.  Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. , 2004, Health technology assessment.

[53]  A. Briggs,et al.  Cost-Effectiveness Acceptability Curves in the Dock , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[54]  Gordon B. Hazen,et al.  Sensitivity Analysis and the Expected Value of Perfect Information , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[55]  F A Sonnenberg,et al.  Toward a Peer Review Process for Medical Decision Analysis Models , 1994, Medical care.

[56]  N. Waugh,et al.  Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. , 2004, Health technology assessment.

[57]  P. Whiting,et al.  A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention. , 2001, Health technology assessment.

[58]  David R. Jones,et al.  Methods for the analysis of quality-of-life and survival data in health technology assessment. , 1999, Health technology assessment.

[59]  Karl Claxton,et al.  Probabilistic analysis and computationally expensive models: Necessary and required? , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[60]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[61]  A. Culyer,et al.  False-negative results in screening programmes: systematic review of impact and implications. , 2000, Health technology assessment.

[62]  S. Mason,et al.  EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy. , 2004, Health technology assessment.

[63]  S. Palmer,et al.  Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. , 2006, Health Technology Assessment.

[64]  J Cowan,et al.  Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. , 2003, Health technology assessment.

[65]  C. Longson,et al.  Cardiac resynchronisation therapy for the treatment of heart failure: NICE technology appraisal guidance , 2007, Heart.

[66]  M Sculpher,et al.  A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. , 2004, Health technology assessment.

[67]  B. Cooper,et al.  Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling. , 2003, Health technology assessment.

[68]  M Sculpher,et al.  Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. , 2005, Health technology assessment.

[69]  H. Gravelle,et al.  Discounting for health effects in cost-benefit and cost-effectiveness analysis. , 2001, Health economics.

[70]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[71]  C. Eiser,et al.  Quality-of-life measures in chronic diseases of childhood. , 2001, Health technology assessment.

[72]  M. Pitt,et al.  The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation. , 2005, Health technology assessment.

[73]  M. Gulliford,et al.  Monitoring blood glucose control in diabetes mellitus: a systematic review. , 2000, Health technology assessment.

[74]  D. Symmons,et al.  The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. , 2005, Health technology assessment.

[75]  R. Murray,et al.  Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. , 2006, Health technology assessment.

[76]  R. Fitzpatrick,et al.  Issues in methodological research: perspectives from researchers and commissioners. , 2001, Health technology assessment.

[77]  A. Grant,et al.  Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions. , 2005, Health technology assessment.

[78]  T. Skinner,et al.  Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review. , 2001, Health technology assessment.

[79]  J. Lord,et al.  Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis. , 1999, Health economics.

[80]  A Briggs,et al.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.

[81]  D. Lamping,et al.  An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. , 2005, Health technology assessment.

[82]  F. Cowan,et al.  Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. , 2000, Health technology assessment.

[83]  J. Heyse,et al.  Use of an angular transformation for ratio estimation in cost-effectiveness analysis. , 2000, Statistics in medicine.

[84]  M. Sculpher,et al.  Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. , 2005, Health technology assessment.

[85]  S. Walters,et al.  Costs and benefits of community postnatal support workers: a randomised controlled trial. , 2000, Health technology assessment.

[86]  J Raftery,et al.  Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. , 2005, Health technology assessment.

[87]  T P Klassen,et al.  The inclusion of reports of randomised trials published in languages other than English in systematic reviews. , 2003, Health technology assessment.

[88]  A. Culyer,et al.  Liquid-based cytology in cervical screening: a rapid and systematic review. , 2000, Health technology assessment.

[89]  E. Murphy,et al.  Qualitative research methods in health technology assessment: a review of the literature. , 1998, Health technology assessment.

[90]  Andrew Briggs,et al.  Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[91]  G. ter Riet,et al.  Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. , 2008, Health technology assessment.

[92]  J. Wight,et al.  Treatments for spasticity and pain in multiple sclerosis: a systematic review. , 2003, Health technology assessment.

[93]  Jennifer A. Roberts,et al.  Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. , 2006, Health technology assessment.

[94]  Stirling Bryan,et al.  Modelling in the economic evaluation of health care: selecting the appropriate approach , 2004, Journal of health services research & policy.

[95]  R Garside,et al.  The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. , 2005, Health technology assessment.

[96]  A. Bagnall,et al.  Effectiveness and cost-effectiveness of acute hospital-based spinal cord injuries services: systematic review. , 2003, Health technology assessment.

[97]  M. Knapp,et al.  Home treatment for mental health problems: a systematic review. , 2001, Health technology assessment.

[98]  J A Kanis,et al.  Treatment of established osteoporosis: a systematic review and cost-utility analysis. , 2002, Health technology assessment.

[99]  P F Sharp,et al.  The value of digital imaging in diabetic retinopathy. , 2003, Health technology assessment.

[100]  M Forshaw,et al.  A critical review of the role of neonatal hearing screening in the detection of congenital hearing impairment. , 1997, Health technology assessment.

[101]  M. Drummond,et al.  Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .

[102]  A E Ades,et al.  Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. , 2006, Health economics.

[103]  A. Grant,et al.  Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence. , 2003, Health technology assessment.

[104]  S. Wessely,et al.  A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. , 2002, Health technology assessment.

[105]  K. Morgan,et al.  Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. , 2004, Health technology assessment.

[106]  P. Bower,et al.  Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. , 2000, Health technology assessment.

[107]  P. Roderick,et al.  The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. , 2003, Health Technology Assessment.

[108]  M. Westwood,et al.  Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. , 2004, Health technology assessment.

[109]  M J Buxton,et al.  Evaluating patient-based outcome measures for use in clinical trials. , 1998, Health technology assessment.

[110]  J Nicholl,et al.  Routine preoperative testing: a systematic review of the evidence. , 1997, Health technology assessment.

[111]  S. Stearns,et al.  Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. , 2003, Health technology assessment.

[112]  David R. Jones,et al.  A systematic review of discharge arrangements for older people. , 2002, Health technology assessment.

[113]  D. Spiegelhalter,et al.  Consensus development methods, and their use in clinical guideline development. , 1998, Health technology assessment.

[114]  M. Pitt,et al.  Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. , 2006, Health technology assessment.

[115]  S. Ebrahim,et al.  Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. , 2004, Health technology assessment.

[116]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[117]  R. Collins,et al.  Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. , 2005, Health technology assessment.

[118]  Bernie J. O'Brien,et al.  In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.

[119]  A. Round,et al.  Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. , 2004, Health technology assessment.

[120]  A E Ades,et al.  Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. , 1999, Health technology assessment.

[121]  R. Milne,et al.  Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. , 2002, Health technology assessment.

[122]  A. Knowles DIABETIC FOOT ULCERATION , 1996 .

[123]  R. Milne,et al.  Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. , 2002, Health technology assessment.

[124]  R. Jordan,et al.  Treatments for fatigue in multiple sclerosis: a rapid and systematic review. , 2000, Health technology assessment.

[125]  A. Culyer,et al.  Newborn screening for inborn errors of metabolism: a systematic review. , 1997, Health technology assessment.

[126]  A H Briggs,et al.  Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.

[127]  A. Thompson,et al.  Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. , 2004, Health technology assessment.

[128]  C. Clar,et al.  Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation. , 2005, Health technology assessment.

[129]  Javier Soto,et al.  HEALTH ECONOMIC EVALUATIONS USING DECISION ANALYTIC MODELING , 2002, International Journal of Technology Assessment in Health Care.

[130]  C. Normand,et al.  A systematic review of the role of bisphosphonates in metastatic disease. , 2004, Health technology assessment.

[131]  M. Petticrew,et al.  Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions. , 1998, Health technology assessment.

[132]  T. Peters,et al.  Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. , 2001, Health technology assessment.

[133]  M. Mugford,et al.  Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views. , 2000, Health technology assessment.

[134]  C. Fowler,et al.  Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. , 2005, Health technology assessment.

[135]  K. Payne,et al.  Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial. , 2002, Health technology assessment.

[136]  A Haycox,et al.  Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. , 2003, Health technology assessment.